title: Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.
abstract: Heparin and low molecular weight heparin (LMWH) derivatives are considered angiogenic factors in ischemic and infarcted myocardium. However, the effect of dalteparin sodium (fragmin, a LMWH derivative) on angiogenesis post infarction has not yet been investigated.Purpose. To assess the effect of systemically-administered dalteparin sodium on left ventricular perfusion and function during remodeling in swine subjected to acute microembolization infarction (MI).Methods. MI was induced in 12 anesthetized female pigs which randomly received dalteparin sodium (12,500U) or placebo through intra-peritoneal osmotic pump, for one week, beginning immediately after the MI. Myocardial perfusion and function were measured using radionuclear scan and echocardiography, respectively, at baseline, immediately post MI, and at 2 and 4 weeks post MI. Dobutamine stress echocardiography was performed 4 weeks post MI. Serum level of basic fibroblast growth factor (bFGF) was analyzed using a commercially available ELISA kit.Results. No differences were observed in myocardial perfusion at all time points following MI. No significant changes were observed in myocardial function and wall motion during the 4 weeks follow-up period, or after dobutamine administration. Serum bFGF did not change throughout the study period.Conclusion. Under the setting of the current experiment, one week of dalteparin sodium administration does not affect myocardial perfusion and function following acute infarction in swine, either at rest or following pharmacological stress.
authors.affiliation: The Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer 52621, Israel. mickeys@post.tau.ac.il
authors.forename: Mickey
authors.initials: M
authors.lastname: Scheinowitz
authors.forename: Yuval
authors.initials: Y
authors.lastname: Heled
authors.forename: Pierre
authors.initials: P
authors.lastname: Chouraqui
authors.forename: Zvi
authors.initials: Z
authors.lastname: Vered
authors.forename: Yfat
authors.initials: Y
authors.lastname: Hayardeni
authors.forename: Arkady
authors.initials: A
authors.lastname: Kotlyar
authors.forename: David
authors.initials: D
authors.lastname: Castel
authors.forename: Shy
authors.initials: S
authors.lastname: Livschitz
authors.forename: Vivian
authors.initials: V
authors.lastname: Barak
authors.forename: Naphtali
authors.initials: N
authors.lastname: Savion
authors.forename: Michael
authors.initials: M
authors.lastname: Eldar
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D017985:Dalteparin / Q000494:pharmacology*; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood; D007274:Injections, Intraperitoneal; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D013552:Swine; D013997:Time Factors; D014463:Ultrasonography; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000925:Anticoagulants; D005346:Fibroblast Growth Factors; D017985:Dalteparin